Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
VLP TherapeuticsVLP Therapeutics is a Maryland-based biotechnology company established in 2012, focused on developing preventative and therapeutic vaccines as well as targeted antibody agents for cancer, infectious diseases, autoimmune conditions, and neurological diseases. The company utilizes next-generation virus-like particle platforms, gene delivery systems, and structure-based antigen design to address unmet global medical needs. Its research pipeline includes vaccine candidates for malaria, dengue, COVID-19, and cancer immunotherapies. The organization is driven by a team with experience in vaccine R&D, clinical development, and collaborative partnerships with prominent academic and government institutions.
VLP Therapeutics is a Maryland-based biotechnology company established in 2012, focused on developing preventative and therapeutic vaccines as well as targeted antibody agents for cancer, infectious diseases, autoimmune conditions, and neurological diseases. The company utilizes next-generation virus-like particle platforms, gene delivery systems, and structure-based antigen design to address unmet global medical needs. Its research pipeline includes vaccine candidates for malaria, dengue, COVID-19, and cancer immunotherapies. The organization is driven by a team with experience in vaccine R&D, clinical development, and collaborative partnerships with prominent academic and government institutions.
Publication Number
US-12636341-B2
Publication Date
2026-05-26
Expiration Date
Abstract
The present disclosure provides a virus like particle comprising a viral structural protein and a galectin epitope peptide, and a composition or vaccine comprising thereof, its use in a medicine, particularly in an immunotherapy.
Core Innovation
The invention describes galectin-targeting immunotherapy in which virus-like particles comprise alphavirus viral structural proteins derived from Chikungunya virus or Venezuelan equine encephalitis virus and include at least one galectin antigen. The galectin antigen is a peptide fragment of galectin-1 or galectin-3, and the virus-like particle framework presents galectin peptide fragments as targeting immunogens.
In the described embodiments, galectin antigens are associated with the alphavirus viral structural protein and are inserted into the envelope protein E3 region. The document frames antigen incorporation with defined residue ranges and furin-site replacement or mutation context for the E3 region, and it provides specific galectin epitope peptide embodiments for galectin-1 and galectin-3 identified by SEQ ID NOs.
The described scope further includes nucleic acid and vector embodiments, and pharmaceutical or vaccine compositions containing the virus-like particles. The invention is described as providing therapeutic and prophylactic use, including a method for treating or preventing cancer or inflammatory disease using the galectin-targeting virus-like particles.
Claims Coverage
The provided claim set includes one independent claim directed to a galectin antigen-displaying virus-like particle and a method use. It covers three main inventive feature layers: the alphavirus structural protein origin, the galectin antigen type and form, and insertion or sequence-defined refinements.
Virus-like particle with alphavirus structural protein and galectin peptide fragment
A virus-like particle comprising an alphavirus viral structural protein derived from Chikungunya virus or Venezuelan equine encephalitis virus and at least one galectin antigen, wherein the at least one galectin antigen is a peptide fragment of galectin-1 or galectin-3.
Galectin antigen inserted into envelope protein E3
The virus-like particle is configured so that at least one galectin antigen is inserted into the envelope protein E3.
Galectin antigen inserted within defined residue ranges
At least one galectin antigen is inserted at particular residue ranges within specified sequence identifiers.
Galectin-1 epitope peptide fragments selected from SEQ ID NOs 9-12
At least one galectin antigen is selected from the specified set of galectin-1 antigen sequences identified as SEQ ID NO: 9, 10, 11, and 12.
Galectin-3 epitope peptide fragments selected from SEQ ID NOs 13-16
At least one galectin antigen is selected from the specified set of galectin-3 antigen sequences identified as SEQ ID NO: 13-16.
Method for treating or preventing cancer or inflammatory disease
A method is provided for treating or preventing cancer or inflammatory disease using the claimed immunotherapy.
The claim coverage centers on a virus-like particle that couples alphavirus structural proteins from Chikungunya virus or Venezuelan equine encephalitis virus with galectin-1 or galectin-3 peptide fragments, with additional coverage for insertion into envelope protein E3, specific SEQ ID-defined peptide selections, and use in treating or preventing cancer or inflammatory disease.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?